Crinetics Pharmaceuticals Announces Launch of Clinical Trial Recruiting Site
Currently, Crinetics Pharmaceuticals is enrolling two Phase 2 studies through their recruiting site – www.theacrobatstudies.com.
ACROBAT EDGE – is an open label exploratory study to evaluate the safety, pharmacokinetics and efficacy of CRN00808 in patients with acromegaly treated with somatostatin analogue based treatment regimens.
ACROBAT EVOLVE – A double-blind, placebo controlled, randomized withdrawal study to evaluate the safety, pharmacokinetics and efficacy of CRN00808 in patients with acromegaly that are responders to octreotide LAR or lanreotide depot.
CRN00808 is a non-peptide, orally bioavailable, somatostatin agonist that is under development for the treatment of acromegaly as an investigational drug. In an initial Phase 1 clinical trial, once daily CRN0080 administration for up to 10 days was shown to result in IGF-1 lowering in healthy volunteers. These new Phase 2 studies represent the first time CRN00808 has been studied in acromegaly patients.
Acromegaly patients can go to the www.theacrobatstudies.com, answer 3 prescreening questions and then a member of the clinical trials team will get in touch with the prospective trial patient to identify study sites that the patient can contact.
Also on the website, there are 3 social media memes that anyone can download and share on Facebook or Twitter. Help “spread the news” for this exciting clinical trial recruiting website.